Chauhan, M., Malik, S.
The aim is to entrap vancomycin hydrochloride used topically for endophthalmitis, in a novel nanovesicular carrier system named spanlastics® to ensure the sustained and intravitreal delivery of the drug in eye over a period of 24 hours to overcome the problem of frequent dosing. To optimize the levels of different process parameters influencing size, polydispersity index (PDI) and encapsulation efficiency (EE %), an experimental design of 34 runs containing 5 central points was selected according to the Box-Behnken statistical design for three factors X1 – Span: tween 80 ratio, X2 – amount of drug, X3 – stirring speed at three levels with one categorical factor, X4 – type of span at two levels. The Design Expert software suggested an optimized formula to be prepared whose overall desirability was 0.950 for span 40. The optimized formulation resulted in entrapment efficiency of 88.12%, vesicle size of 180.5 nm and PDI of 0.21. In-vitro release study of the optimized spanlastics® suggested extended release for 24 hours and followed higuchi release model with R2 value of 0.9963. Further ex-vivo release study showed better corneal permeability and sustained release for 24 hours. Ocular safety of the surfactant based vesicular carrier was also established by draize irritancy test.
Ocular Delivery, Spanlastics®, Span 40, Span 60, Tween 80
Cite This Article
Chauhan, M., Malik, S. (2016). Formulation and Optimization of Novel Elastic Nano-Vesicular Carrier of Vancomycin Hydrochloride for Enhanced Corneal Permeability, International Journal for Pharmaceutical Research Scholars (IJPRS), 5(4), 88-100.